Exhibit 99.1 10x Genomics Reports Second Quarter 2024 Financial Results Recent Highlights Second Quarter 2024 Financial Results 2024 Financial Guidance Webcast and Conference Call Information PLEASANTON, Calif. August 8, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024. • Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily driven by st ...

PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions. Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to joi ...

PLEASANTON, Calif. , Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily driven by stronger contributions from consumables. Began shipping Xenium Prime 5K, which measures 5,000 genes and features an enhanced chemistry to deliver excellent per-gene ...

● . ● Torex Gold Reports Q2 2024 Results Another consistent quarter of safe and reliable production; on track to deliver on full-year operational guidance August 07, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc. (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - August 7, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the three and six months ended June 30, 2024. Torex ...

In its upcoming report, 10x Genomics (TXG) is predicted by Wall Street analysts to post quarterly loss of $0.47 per share, reflecting an increase of 11.3% compared to the same period last year. Revenues are forecasted to be $150.9 million, representing a year-over-year increase of 2.8%. The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial ...

Wall Street expects a year-over-year increase in earnings on higher revenues when 10x Genomics (TXG) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 8, 2024, might help the stock move higher if these key numbers are better than expec ...

● Torex Gold Provides Q2 2024 Update on Media Luna Project (All amounts expressed in U.S. dollars unless otherwise stated) "Development of Media Luna continues to track to schedule, with first production of copper concentrate anticipated by year end and commercial production expected in Q1 2025. As at the end of June, Media Luna was 78% complete across engineering, procurement, underground development/construction, and surface construction, compared to 69% at the end of March. "With completion of Media Luna ...

Why TXG Could Witness a Solid Upside Here's What You Should Know About Analysts' Price Targets The average comprises 16 short-term price targets ranging from a low of $16 to a high of $55, with a standard deviation of $12.57. While the lowest estimate indicates a decline of 20% from the current price level, the most optimistic estimate points to a 175% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard d ...

10x Genomics scored a strong price increase on investors' optimism surrounding the recent announcement that its Xenium In Situ platform was used in a study published in the Journal of Dental Research, offering novel insights into cellular mechanisms regulating the formation of the secondary palate. Additionally, the company is slated to report its second-quarter 2024 financial results on Aug 8, after the closing bell. The Zacks Consensus Estimate for the second quarter revenue and earnings indicate a 3.1% a ...

Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event. Disclosure Information SOURCE 10x Genomics, Inc. PLEASANTON, Calif., July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the second quarter ended June 30, 2024 after market close on Thur ...